**Table S1. Questions posed to respondents.**

|  |
| --- |
| **DEMOGRAPHICS AND EXPERTISE IN ED-SCLC TREATMENT*** Which is your medical specialty?
* How long have you been working as a radiation oncologist?
* What type of healthcare institution do you work for?
* What percentage of your time do you spend on lung cancer disease?
* In which italian geographical area do you practice?
* Which medical figure is usually responsible for/handle patients diagnosis and staging in your Centre?
* Do you have a MDT discussion dedicated SCLC cases in your Institution?
* How many pts with newly diagnosed SCLC came to your department in the last year?
* How many pts with newly diagnosed ES-SCLC came to your department in the last year?
 |
| **MANAGEMENT OF ED-SCLC****Role of systemic treatment** * Which is your first therapeutic approach in case of pts with ED- SCLC and PS=0-1?
* What CHT regimen do you prefer in your clinical practice in case of patients with ED- SCLC and PS=0-1?
* What CHT regimen do you prefer in your clinical practice in case of patients with ED- SCLC and PS=2 (due to tumour-related symptoms)?
* Considering the combination of CHT and IT in patients with ES-SCLC, how many cycles of CHT do you usually plan in your clinical practice?

**Role of PCI*** Considering the results from IT plus CHT in ES-SCLC and given the possibility of maintenance therapy, do you consider PCI in these patients in your clinical practice?
* If prescribed, when PCI is usually performed in your clinical practice?
* If prescribed, which radiation technique do you usually choose for PCI?

**Role of thoracic consolidative RT*** Taking into account the results achieved by consolidation IT in ES-SCLC patients, do you consider RT for intrathoracic disease?
* Which schedule do you usually choose for thoracic RT in ES-SCLC patients?
* When do you usually start thoracic RT in ES-SCLC?

**Management of oligoPD*** What treatment do you usually recommend in case of ES-SCLC patient with intracranial oligoPD during manteinance IT?
* What treatment do you usually recommend in case of ES-SCLC patient with extracranial oligoPD during manteinance IT?
 |

 *pts* patients, M*DT* multidisciplinary team, *SCLC* small cell lung cancer, *ES-SCLC* extended stage small cell lung cancer, *PS* performance status, *CHT* chemotherapy, *IT* immunotherapy, *PCI* prophylactic cranial irradiation, *RT* radiation therapy, *oligoPD* oligoprogression disease